Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients
2024 ASCO Annual Meeting
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
What we are going to look at is to determine the trends in and use of primary hormonal therapy use, and also long-term survival outcomes for hormonal therapy in premenopausal patient with early stage endometrial cancer. The design of this study is retrospective cohort study, and we use national cancer database which registered around 70% of newly diagnosed cases in the US. We have two major parts in this study and the fourth one is looking at the trends in and patterns of use of primary hormonal therapy in the premenopausal patient with early stage endometrial cancer. And the second one is survival outcome for the patient with early stage endometrial cancer. We included patients 18 to 49 years old and clinical stage 1 endometrial cancer and grade one [inaudible 00:01:01] 2 endometrial cancer. Main finding of our study is the utilization rate of primary hormonal therapy rose from 4% to 5% around 2004 to 2010, and it's going up to 12% to 14% in 2020.
Younger age, non-white race patients who live in metropolitan area, patient who are treated at academic cancer center, patient who are treated at the facilities located at Northeast area in the US were associated with primary hormonal therapy use. In terms of tumor characteristics, grade 1 and stage 1A were associated with primary hormonal therapy use. For survival outcomes, the propensity score match cohort is well-balanced between the two primary treatment group. Overall, after 10 year follow up, the survival rate was decreased by 4.1% in hormonal therapy group compared with hysterectomy group. Hazard ratio was 1.84.
In age subgroup, patient younger than 40 years old, the two primary treatment group of the survival rate was similar at any time point, five year and 10 year point. Surprisingly among age 40 to 49, the survival rate was inferior in hormonal therapy group then hysterectomy group at five year point and 10 year point. Hazard ratio was 4.94.
To conclude, given the growing number of patient with early stage endometrial cancer who may desire fertility preservation, we need to consider potentially poorer prognosis when patients and provider select the primary hormonal therapy use. Shared decision making is further needed for this space and also prospective study with large sample sites should be needed for making this evidence more robust.
The ASCO Post Staff
Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).
The ASCO Post Staff
Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).
The ASCO Post Staff
Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).
The ASCO Post Staff
Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.